
Biolidics said on that it has partnered with Japanese diagnostics firm Sysmex on the development of a liquid biopsy-based cancer test for the Asian market.
The companies have been collaborating since 2016 on a liquid biopsy system that combines Biolidics’ ClearCell FX1 automated label-free circulating tumor cell separation and enrichment platform with Sysmex’s MI-FCM molecular imaging flow cytometer system.
Under the terms of their latest agreement, the companies will jointly develop a laboratory-developed test based on their respective technologies. Following clinical validation by Biolidics affiliate SAM Laboratory, Biolidics — formerly known as Clearbridge BioMedics — will commercialize the test in Asian markets outside of Japan.
Additional terms were not disclosed.
Source: https://www.genomeweb.com/
Related presentations
Login to access to our Analysts' presentations on all expertise
Related Reports and Monitors
Organs-On-Chips Market and Technology Landscape 2019
Market & Technology
Inkjet Printheads: Dispensing Technologies & Market Landscape 2019
Market & Technology